{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T03:08:40Z","timestamp":1776136120646,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T00:00:00Z","timestamp":1637020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Allergy Asthma Clin Immunol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Bullous pemphigoid (BP) is a potentially life-threatening autoimmune blistering disease which is characterized by autoantibodies against hemidesmosomal proteins of the skin and mucous membranes. In recent years, the role of eosinophil and immunoglobulin E autoantibodies have been further elucidated in BP, and have been considered potential therapeutic targets.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentations<\/jats:title>\n                <jats:p>A 67-year-old male presented with erythematous bullous eruption. The skin eruption was located on whole body, and suggested BP. Peripheral blood eosinophil count and total immunoglobulin E markedly elevated in initial laboratory findings. Topical and systemic steroid (methylprednisolone 2\u00a0mg\/kg\/day) treatment was started, and his skin symptoms worsened repeatedly, whenever systemic steroid were reduced. On admission day 29, reslizumab (anti-interleukin-5) 3.5\u00a0mg\/kg was administered intravenously to the patients. The bullous skin lesion began to improve rapidly, and methylprednisolone (8\u00a0mg\/day) was reduced without any worsening of symptoms during two doses of reslizumab.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We report a case of successful treatment response to reslizumab administration in a patient with BP. Further studies are needed to confirm the role of anti-interleukin-5 as a treatment for BP in the future.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13223-021-00619-1","type":"journal-article","created":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T14:04:23Z","timestamp":1637071463000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Successful induction treatment of bullous pemphigoid using reslizumab: a case report"],"prefix":"10.1186","volume":"17","author":[{"given":"Hyo-In","family":"Rhyou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Song-Hee","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hee","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,11,16]]},"reference":[{"issue":"2","key":"619_CR1","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/abd1806-4841.20199007","volume":"94","author":"D Miyamoto","year":"2019","unstructured":"Miyamoto D, Santi CG, Aoki V, Maruta CW. Bullous pemphigoid. An Bras Dermatol. 2019;94(2):133\u201346.","journal-title":"An Bras Dermatol"},{"issue":"10","key":"619_CR2","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.3390\/biom10101432","volume":"10","author":"F Moro","year":"2020","unstructured":"Moro F, Fania L, Sinagra JLM, Salemme A, Zenzo GD. Bullous pemphigoid: trigger and predisposing factors. Biomolecules. 2020;10(10):1432.","journal-title":"Biomolecules"},{"issue":"4","key":"619_CR3","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.ad.2012.10.022","volume":"105","author":"IF de Vega","year":"2014","unstructured":"de Vega IF, Iranzo-Fern\u00e1ndez P, Mascar\u00f3-Galy JM. Bullous pemphigoid: clinical practice guidelines. Actas Dermosifiliogr. 2014;105(4):328\u201346.","journal-title":"Actas Dermosifiliogr"},{"key":"619_CR4","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3389\/fmed.2018.00201","volume":"5","author":"KT Amber","year":"2018","unstructured":"Amber KT, Valdebran M, Kridin K, Grando SA. The role of eosinophils in bullous pemphigoid: a developing model of eosinophil pathogenicity in mucocutaneous disease. Front Med. 2018;5:201.","journal-title":"Front Med"},{"issue":"5","key":"619_CR5","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jid.2017.11.031","volume":"138","author":"L Lin","year":"2018","unstructured":"Lin L, Hwang BJ, Culton DA, Li N, Burette S, Koller BH, et al. Eosinophils mediate tissue injury in autoimmune skin disease bullous pemphigoid. J Invest Dermatol. 2018;138(5):1032\u201343.","journal-title":"J Invest Dermatol"},{"key":"619_CR6","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.3389\/fimmu.2019.01506","volume":"10","author":"G Genovese","year":"2019","unstructured":"Genovese G, Zenzo GD, Cozzani E, Berti E, Cugno M, Marzano AV. New insights into the pathogenesis of bullous pemphigoid: 2019 update. Front Immunol. 2019;10:1506.","journal-title":"Front Immunol"},{"key":"619_CR7","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1111\/exd.13416","volume":"26","author":"D Simon","year":"2017","unstructured":"Simon D, Borradori L, Simon HU. Eosinophils as putative therapeutic targets in bullous pemphigoid. Exp Dermatol. 2017;26:1187\u201392.","journal-title":"Exp Dermatol"},{"issue":"1","key":"619_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/exd.12883","volume":"25","author":"KN Messingham","year":"2016","unstructured":"Messingham KN, Wang JW, Holahan HM, Srikantha R, Aust SC, Fairley JA. Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid. Exp Dermatol. 2016;25(1):50\u20135.","journal-title":"Exp Dermatol"},{"key":"619_CR9","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1172\/JCI117196","volume":"93","author":"M Stahle-Backdahl","year":"1994","unstructured":"Stahle-Backdahl M, Inoue M, Guidice GJ, Parks WC. 92-kD gelatinase is produced by eosinophils at the site of blister formation in bullous pemphigoid and cleaves the extracellular domain of recombinant 180-kD bullous pemphigoid autoantigen. J Clin Invest. 1994;93:2022\u201330.","journal-title":"J Clin Invest"},{"key":"619_CR10","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1038\/jid.2015.106","volume":"135","author":"N Kunsleben","year":"2015","unstructured":"Kunsleben N, R\u00fcdrich U, Gehring M, Novak N, Kapp A, Raap U. IL-31 induces chemotaxis, calcium mobilization, release of reactive oxygen species, and CCL26 in eosinophils, which are capable to release IL-31. J Invest Dermatol. 2015;135:1908\u201311.","journal-title":"J Invest Dermatol"},{"key":"619_CR11","doi-asserted-by":"publisher","first-page":"7585","DOI":"10.4049\/jimmunol.179.11.7585","volume":"179","author":"HB Wang","year":"2007","unstructured":"Wang HB, Ghiran I, Matthaei K, Weller PF. Airway eosinophils: allergic inflammation recruited professional antigen-presenting cells. J Immunol. 2007;179:7585\u201392.","journal-title":"J Immunol"},{"key":"619_CR12","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.3389\/fimmu.2017.01781","volume":"8","author":"A Lin","year":"2017","unstructured":"Lin A, Lore K. Granulocytes: new members of the antigen-presenting cell family. Front Immunol. 2017;8:1781.","journal-title":"Front Immunol"},{"key":"619_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.alit.2020.02.002","volume":"69","author":"H Nagase","year":"2020","unstructured":"Nagase H, Ueki S, Fujieda S. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis. Allergol Int. 2020;69:178\u201386.","journal-title":"Allergol Int"},{"issue":"1","key":"619_CR14","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/1939-4551-7-32","volume":"7","author":"M Mukherjee","year":"2014","unstructured":"Mukherjee M, Sehmi R, Nair P. Anti-IL5 therapy for asthma and beyond. World Allergy Organ J. 2014;7(1):32.","journal-title":"World Allergy Organ J"},{"key":"619_CR15","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/all.13451","volume":"73","author":"M Hassani","year":"2018","unstructured":"Hassani M, Koenderman L. Immunological and hematological effects of IL-5(R\u03b1)-targeted therapy: an overview. Allergy. 2018;73:1979\u201388.","journal-title":"Allergy"},{"issue":"2","key":"619_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-018-0401-6","volume":"20","author":"N Kremer","year":"2019","unstructured":"Kremer N, Snast I, Cohen ES, Hodak E, Mimouni D, Lapidoth M, et al. Rituximab and omalizumab for the treatment of bullous phemphigoid: a systemic review of the literature. Am J Clin Dermatol. 2019;20(2):209\u201316.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"619_CR17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1007\/s40257-017-0264-2","volume":"18","author":"P Bernard","year":"2017","unstructured":"Bernard P, Antonicelli F. Bullous pemphigoid: a review of its diagnosis, associations and treatment. Am J Clin Dermatol. 2017;18(4):513\u201328.","journal-title":"Am J Clin Dermatol"},{"key":"619_CR18","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/all.14425","volume":"76","author":"L Agache","year":"2021","unstructured":"Agache L, Akdis CA, Akdis M, Canonica GW, Casale T, Chivato T, et al. EAACI biological guidelines-recommendations for severe asthma. Allergy. 2021;76:14\u201344.","journal-title":"Allergy"},{"issue":"3","key":"619_CR19","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1111\/all.13950","volume":"75","author":"D Simon","year":"2020","unstructured":"Simon D, Yousefi S, Cazzaniga S, B\u00fcrgler C, Radonjic S, Houriet C, et al. Mepolizumab failed to affect bullous pemopigoid: a randomized, placebo-controlled, double-blind phase 2 pilot study. Allergy. 2020;75(3):669\u201372.","journal-title":"Allergy"}],"container-title":["Allergy, Asthma &amp; Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13223-021-00619-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13223-021-00619-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,16]],"date-time":"2021-11-16T14:06:17Z","timestamp":1637071577000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacijournal.biomedcentral.com\/articles\/10.1186\/s13223-021-00619-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,16]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["619"],"URL":"https:\/\/doi.org\/10.1186\/s13223-021-00619-1","relation":{},"ISSN":["1710-1492"],"issn-type":[{"value":"1710-1492","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,16]]},"assertion":[{"value":"16 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The work was written obeying the principles ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patient consented to the publication of this case report. All authors consented to the publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None of the authors report potential competing interests with this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"117"}}